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Tumor spheroids or microtumors are important three-dimensional (3D) in vitro tumor 
models, possessing in vivo-like tumor microenvironment. Microtumors are widely applied in 
the fields of fundamental cancer research, drug discovery and precision medicine. In precision 
medicine tumor spheroids derived from patient tumor cells represent a promising system for 
drug sensitivity and resistance testing. Current methods for 3D spheroids fabrication and 
screening require large numbers of cells and compounds and not always result in formation of 
a single spheroid per well. In this study we demonstrate an application of the Droplet 
Microarray platform, based on hydrophilic-superhydrophobic patterning, in combination with 
the method of hanging droplet for the formation of highly miniaturized single-spheroid-
microarrays. We demonstrate formation of spheroids from several commonly used cancer cell 
lines in 100 nL droplets starting with as few as 150 cells per spheroid within 24 - 48 hours. 
Established methodology carries a potential to be adopted for routine workflows of high-
throughput compound screening in 3D cancer spheroids or microtumors, which is crucial for 




Tumor spheroids or microtumors consist of cancer cells that self-organize into three-
dimensional (3D) tumor-like spherical structures.[1] They find wide application as 3D in vitro 
tumor models in the fields of fundamental cancer research, drug discovery and precision 
medicine.[2-4] Compared to 2D monolayer cultures, tumor spheroids closer represent in vivo 
like tumor microenvironment. Extracellular matrix (ECM) proteins produced by cells in three-
dimensional structure, as well as cell-cell contact provide mechanical properties that are 
essential for morphology, expression profile, proliferation and drug response of cells residing 
in microtumor.[5][6-9] In addition, microtumor environment differs biochemically from 2D 
monolayer, and characterized by low oxygen, low pH and low glucose content.[10, 11] This 
different biochemical characteristics influence cell biology and have been shown to increase 
invasiveness, induce proliferation and drug resistance of cancer cells.[12-14] Limitation of 
oxygen and nutrients diffusion within a tumor spheroid results in developing of a hypoxic 
region and a necrotic core, similar to that in in vivo tumors.[4, 7-9, 15-17] Therefore, cells 
grown in spheroid models demonstrate properties that resemble those of cancer cells found in 
naturally occurring tumors. This close resemblance of the in vivo tumor microenvironment 
makes tumor spheroids an important physiologically relevant in vitro model, which has been 
widely applied for testing of anti-cancer compounds, investigating the mechanism of drug 
resistance and studying growth kinetics and metabolism of tumors to mention a few 
examples.[18]   
Drug sensitivity and resistance testing using tumor spheroids formed in vitro has shown 
drug responses similar to those found in vivo.[4, 8, 9] Previous studies showed reduced 
sensitivity of cancer cells towards anti-cancer therapy when cultured in 3D spheroids compared 
to 2D cell culture. Detailed investigation of mechanism of drug sensitivity difference between 
3D and 2D environments revealed that cells cultured in 3D cell models possessed enhanced 
gene expression profile, which correlated with increased mutation rates and the ability of tumor 
cells for invasion and formation of metastasis.[3, 15, 19-21] Routine use of 3D tumor spheroids 
model for drug testing can result in reduction of false positive and negative results, therefore 
decreasing usually high failure rates and costs of drug development, and ultimately leading to 
reduction of unnecessary animal experiments.[3, 4, 21, 22] In order to employ spheroid models 
for routine screening applications, it is necessary to have reliable and affordable high-
throughput platforms enabling formation, culturing and screening of hundreds of uniform 
spheroids in one-spheroid-per-well format. 
Current standard methods for 3D spheroids fabrication include spinner flasks, bacterial 
grade dishes, ultra-low attachment (ULA) plates and method of hanging drop.[8, 17, 21-23] 
Using spinner flasks, bacterial grade dishes, and ultra-low attachment (ULA) plates result in 
formation of multiple spheroids per well/plate that show high variability in size. In addition, 
spheroids obtained from spinner flasks and bacterial grade dishes have to be manually plated 
into microtiter plates for screening applications, limiting their applicability for high-throughput 
screening applications. [17, 20, 22] Method of hanging droplet allows for the generation of 
homogeneous spheroids in one-spheroid-per-drop format and compatible with standard liquid 
handling robotics.[27]  Usually  it is performed using standard micro titer plate formats of 96- 
and 384-well plates and requires from 30 to 100 µL of culturing volume resulting in high 
consumption of compounds, reagents and valuable cells. In addition, it is necessary to transfer 
spheroids to a multiwall plate for imaging analysis. 
Reduction of the screening costs by reducing consumption of compounds, reagents and 
cells is of ultimate importance for both industrial and academic environments. In addition, 
reducing cell numbers is especially critical in case of screening of spheroids derived from rare 
cells, such as primary patient tumor cells obtained via biopsy for example. Drug sensitivity and 
resistance test, where tumor spheroids derived from patient tumor cells are tested against a panel 
of anti-cancer drugs with a goal to identify suitable therapy for each patient, is a promising test 
in precision cancer medicine.[28] Therefore, a high-throughput platforms that allow for facile 
formation and screening of uniform spheroids in one-spheroid-per-well format in highly 
miniaturized format is critical for implementation of tumor spheroids as a model for routine 
screening applications. 
A lot of progress has been made in developing novel miniaturized methods for the 
formation and screening of spheroids. Such miniaturized systems include microfluidic devices, 
scaffold-based microarrays and micro-engineered hanging drop arrays.[8](21, 23, 25, 26) 
Microfluidic-based systems enable facile formation and long-term culturing of uniform 
spheroids. (16, 24) The main advantage of these systems is a possibility to create a complex 
perfusion organ-on-a-chip system. However, the drawback of microfluidic platforms is limited 
compatibility with screening of large compound libraries since drugs have to be introduced to 
the spheroids using valves. [16, 24] Scaffold-based microarrays and micro-engineered hanging 
drop arrays enable formation of homogeneous spheroids in volumes down to 1 µL using low 
cell numbers and demonstrate high compatibility with standard liquid handling robotics and 
automated workflow.[21, 23, 25, 26] Some of these  platforms, however, still have limitations. 
For example, it is challenging to retrieve spheroids from scaffolds fur further analysis (22, 27) 
and some of the materials used in those platforms such as e.g. PDMS, showed non-specific 
absorption of compounds, especially in case of hydrophobic substances, resulting in decreasing 
of drug efficacy during the screening. (23, 27, Small molecule absorption by PDMS in the 
context of drug response bioassays.) 
Recently, we developed the Droplet Microarray (DMA), a miniaturized platform for 
cell-based high-throughput screenings.[29-34] The Droplet Microarray consists of an array of 
hydrophilic spots on superhydrophobic background and exhibits extreme contrast in wettability 
between both of these areas. Due to this extreme contrast a high-density array of homogeneous, 
separated and stable nano-droplets can be formed on the surface of the Droplet Microarray. 
Each of these droplets can trap cells and serve as a reservoir for performing individual biological 
experiments. In the current study, we utilized the DMA platform to establish fast and highly 
miniaturized system for screening of single microtumors. We demonstrate formation of single-
spheroid arrays from several commonly used cancer cell lines in 100 nL droplets within 24 - 48 
hours starting only with 150 cells per spheroid. We perform drug treatment on microtumors 
formed from HeLa cells, and compare the response of HeLa cells cultured in 3D spheroids with 




Formation of spheroids on the DMA platform 
DMA slide consists of a glass slide patterned with an array of hydrophilic spots (water 
contact angle (WCA) ≤ 10o)[30] separated by superhydrophobic (advancing and receding 
WCAs ≥ 150° and sliding WCA ≤ 5o)[30] borders (Fig. 2a). In this work we used DMA slides 
with dimension of 25 x 75 mm containing 588 square hydrophilic spots with side length of 1 
mm (Fig. 2a,b). Due to the extreme difference in water affinity of hydrophilic and 
superhydrophobic parts of the surface an array of separated and homogeneous droplets is 
formed on DMA surface spontaneously by applying aqueous solutions onto the surface (Fig. 
2a)[30-32]. This effect is known as discontinuous dewetting[35]. Previously we demonstrated 
formation of arrays of homogeneous separated droplets containing cells using the effect of 
discontinuous dewetting[31]. Here, we utilized both discontinuous dewetting (Fig. 1a, upper 
panel) and a non-contact liter dispenser to print cells directly into each hydrophilic spot (Fig. 
1a, bottom panel). In case of manual seeding, cells were seeded in approximately 80 nL 
droplets[31], in case of using dispenser, cells were seeded in 100 nL droplets. After cells were 
seeded, the DMA slides were turned upside down and placed on a slide holder to create an array 
of hanging droplets (Fig.1a, 2b). The slide holder with the DMA slide was placed into a standard 
10 cm Petri dish containing buffer and closed with a lid containing a humidified pad preventing 
evaporation of the droplets during culturing (see experimental section). Cells were incubated in 
a standard cell culture incubator. Using this simple and miniaturized system we were able to 
create a single-spheroid-array in nanoliter droplets within 24-48 hours (Fig. 2 c, d). Such single-
cell spheroid array can be used for compound treatment followed by microscopy analysis 
directly on the DMA slide, where each spheroid can be addressed individually (Fig. 1b). 
Alternatively, spheroids can be easily collected from the wall-less surface by washing them 
down in Petri dish or other container for further experiments or analysis (Fig. 1c). Thus, DMA 
slides can be not only used as a platform for screening of spheroids, but also as a platform for 
fabrication of hundreds of homogeneous single spheroids that can be further used for various 
applications.   
We successfully formed spheroids from several cell types including MCF-7, HEK293 
and HeLa (Fig. 2c, 3). Size distribution of formed spheroids across an array has corresponded 
to Poisson distribution with about 14% deviation of diameter and was comparable between both 
manual and automated seeding methods (Fig. 2d). Size of spheroids was dependent on initial 
cell number in the droplets and could be controlled by changing initial cell seeding 
concentration (Fig. 3c).  
We monitored the growth and viability of spheroids over several days of culturing 
without medium exchange (Fig. 3 a, b, e, f). From 24 hours to 96 hours of culture the diameter 
of HeLa spheroids increased from 70±10 µm to 100±15 µm, while that of HEK 293 decreased 
from 170±10 to 140±10 µm and of MCF-7 decreased from 140±20 µm to 110±20 µm (Fig. 3 
a, b). We observed that viability of spheroids formed from all three cell types was above 90% 
up to 7 days of culturing without medium exchange (Fig. 3 e, f). By addition of fresh medium 
using non-contact dispenser it might be possible to extend culturing time of spheroids beyond 
7 days.  
 
Drug treatment of spheroids on the DMA platform 
As a next step we performed treatment of spheroids formed from HeLa cells with three 
different anti-cancer compounds (doxorubicin, oxaliplatin and 5-fluoracil) and compared dose-
response of HeLa spheroids and HeLa cells grown in 2D monolayer (Fig. 4). HeLa cells were 
seeded using the liquid dispenser in amount of 150 cells per 100 nL droplets and incubated in 
hanging droplets for 48 hours to allow spheroid formation. Afterwards, spheroids were treated 
with drugs by dispensing 50 nL of compounds diluted in culture medium till desired 
concentrations (see experimental section) and incubating arrays for 72 hours. For 2D cell 
culture Hela cells were dispensed with a liquid dispenser onto a DMA slide and incubated in 
the upright position for 5 hours to allow cells to attach to the surface, followed by treatment 
with the same concentrations of compounds as in the case of spheroids before culturing for 72 
hours. Then cells were stained with Calcein and propidium iodide (PI) for visualization of live 
and dead cells, respectively. The dose-response curves are shown in Figure 4 and demonstrate 
a clear dose-dependent effect of all three compounds on viability of HeLa cells grown both in 
3D and 2D formats (Fig. 4). HeLa cells grown in spheroids were more resistant to drug 
treatment compared to 2D monolayer culture (Fig. 4): for doxorubicin IC50 were ~6 µM and 
<0.05 µM; for oxaliplatin 1.5 µM and ~0.05 µM; for 5-fluoruracil 1 µM and between 0.1 and 
0.5 µM for 3D and 2D cell culture, respectively. Increased resistance of tumor spheroids to anti-
cancer compounds compared to monolayer culture of the same type of cells was reported 
multiple times previously (Ma 2012, Multicellular tumor spheroids as an in vivo-like tumor 
model for three-dimensional imaging of chemotherapeutic and nano material cellular 
penetration; Mohapatra 2016 Spectral mapping of 3D multi-cellular tumor spheroids: time-
resolved confocal microscopy; Shi 2018 Facile Tumor Spheroids Formation in Large Quantity 
with Controllable Size and High Uniformity).  
Discussion and conclusion 
In the current study a facile methodology for fast and miniaturized drug screenings using 
arrays of single cancer spheroids formed in nanoliter droplets on the Droplet-Microarray 
platform was demonstrated. Formation of spheroids from several commonly used cancer cell 
lines in 100 nL droplets within 24 - 48 hours starting only with 150 cells per spheroid was 
shown. To evaluate the possibility of miniaturized drug screenings on cancer cell spheroids, the 
drug treatment of HeLa cells-based spheroids was performed, and clear dose-responses to three 
different anti-cancer compounds were observed. The spheroids could be cultured for up to 7 
days with over 90% viability without exchange of the medium. The size of spheroids could be 
controlled by varying the initial number of cells per a single nanoliter droplets. Established 
methodology offers a number of advantages compared to existing platforms. For example, 
miniaturization down to 100 nL per droplet can result in up to 99% savings of compounds, 
reagents, cells compared to microtiter plates. The possibility to use only 150 cells per spheroid 
can be crucial when working with rare and hard to expand cells, such as primary patient derived 
tumor cells. This makes this system attractive for drug sensitivity and resistance tests performed 
in 3D on patient-derived tumor cells, which in turn an important milestone for personalized 
medicine applications. The DMA platform is uniquely suited for the formation of single-
spheroid microarrays with uniform spheroid size as opposed to many other methodologies 
including ULA plates, where number and size of formed spheroids per well cannot be defined. 
Another advantage is the possibility to perform microscopy of spheroids directly on the DMA 
slides without the need to transfer them into microtiter plates. Due to the small droplet size the 
positioning of spheroids is fixed, which also simplifies both the microscopy and image 
processing. Last but not least, formed homogeneous cell spheroids can be conveniently 
collected into a flask for further experiments, which is important for various applications 
ranging from in vitro tests to regenerative medicine. Thus, we believe that the established 
single-spheroid microarrays can be adopted for screening workflows in fundamental research, 





Figure 1. Schematics demonstrating the fabrication and screening of spheroids on the Droplet-
Microarray (DMA) platform. (a)  Manual cell seeding and seeding by dispensing followed by 
growing spheroids in hanging droplets. (b) Compound screening using single-spheroid-









Figure 2. (a) Photograph of an array of water droplets formed on a DMA slide. Scale bar: 1 
mm. (b) DMA slide in the hanging droplet format. (c) Microscope image of an array of 13 x 13 
droplets containing single spheroids. Scale bar: 1 mm. Insert: 0.5 mm. (d) Graphs showing 
distribution of spheroids’ diameters (196 spheroids formed on a single DMA slide). Spheroids 









Figure 3. Fabrication and culturing of spheroids on the Droplet-Microarray (DMA) platform. 
(a) Brightfield microscope images of spheroid formed from MCF-7, HEK 293 and HeLa cells 
24, 48, 72 and 96 hours after cell seeding. Scale bar: 100 µm. (b) Diameter of spheroids obtained 
from MCF-7, HEK 293 and HeLa cell lines cultured for 96 hours in 80 nL droplets. The initial 
cell number was on average 150 cells per spheroid. (c) Brightfield microscope images of 
spheroids formed from HEK 293 and MCF-7 cell lines starting from about 60, 150 and 350 
cells per spheroid. Scale bar: 100 µm. (d) Diameter of spheroids obtained from HEK 293 and 
MCF-7 cell lines starting from different initial cell numbers. (e) Microscope images of HEK 
293 spheroids cultured on the DMA for 1, 2, 3, 7 and 10 days without medium exchange. 
Spheroids were stained with Calcein AM and propidium iodide (PI). Scale bar: 100 µm. (f) 
Viability of spheroids formed from HEK 293 cells cultured on the DMA without medium 
exchange for 10 days.     
 
 
Figure 4. Treatment of spheroids on the Droplet-Microarray (DMA) platform with anti-cancer 
drugs. (a) Dose-dependent effect of doxorubicin, oxaliplatin and 5-fluorouracil on HeLa 
spheroids. Initial cell number: about 150 cells per spheroid. Spheroids were formed for 72 
hours, followed by addition of drugs using non-contact liquid dispenser and incubating of 
spheroids for 48 h before staining and microscopy analysis. (b) Representative microscope 
images of HeLa spheroids treated with different concentrations of drugs. Scale bar: 100 µm. (c) 
Dose-dependent effect of doxorubicin, oxaliplatin and 5-fluorouracil on HeLa cells cultured in 
2D monolayer. Initial cell number: about 150 cells per spot. Cells were cultured on the DMA 
slide for 24 hours followed by addition of drugs using non-contact liquid dispenser and 
incubating of cells for 48 h before staining and microscopy analysis. (d) Representative 





Cell culture  
Hela, MCF7 and HEK293 T cells were cultured in DMEM supplemented with 10% FCS 
and 1% penicillin/streptomycin.  Cells were cultured in 10 cm cell culture dishes and were split 
every 2-3 days.  
 
Seeding cells and formation of spheroids on Droplet-Microarrays 
 DMA slides were purchased from Aquarray GmbH (Eggenstein-Leopoldshafen, 
Germany). Before cell culture DMA slides were sterilized with 70% ethanol and dried under 
the clean bench. For seeding on DMA slides cells were trypsinized and diluted with DMEM 
containing 15% FCS and 1% penicillin/streptomycin till concentration of 2,5x105 cells/mL and 
1,5x106 cells/mL for manual and automated seeding, respectively. For manual seeding DMA 
slide was placed into Petri dish and 1,7 mL of cell suspension was applied onto each field 
containing 196 spots and incubated for 30 seconds. Afterwards Petri dish was slightly tilted 
letting big droplet of cell suspension roll off the slide, resulting in spontaneous droplet 
formation containing cells. For culturing cells in 2D Petri dish was closed with humidifying lid 
containing humidifying pad wetted with PBS to avoid evaporation and placed to cell culture 
incubator immediately. For culturing cells in 3D DMA slide containing cells was placed on 
specially designed table in upside down position. Table was placed into Petri dish containing 
10 mL of PBS and closed with humidified lid. Petri dish was placed in cell culture incubator 
immediately after seeding. For automated cell seeding cells were dispensed in amount of 150 
cells per 100 nL droplets with I-DOT dispenser (Dispendix GmbH). After printing DMA slide 
was placed in Petri dish either in upright or on the special table in upside down position for 2D 
and 3D cell culture, respectively.  
 
Imaging of spheroids 
For imaging DMA slides containing spheroids were placed either into Petri dish or a 
four-well dish (Thermo Scientific Nunc) in upright position. Imaging was performed with 
Keyence BZ-9000 (KEYENCE, Osaka, Japan) and with Olympus IX81 microscope (Olympus, 
Tokyo, Japan). The images were taken at 6,4 × magnification, in three different channels: 
brighfield, mCherry for PI staining, and green fluorescent protein GFP, for CalceinAM staining.  
 
Live/dead staining of spheroids 
For live/dead staining of spheroids 50 nL of staining solution containing 1 μg/mL 
propidium iodide (PI) (Invitrogene, Merelbeke, Belgium) and 1,5 μg/mL CalceinAM (Thermo 
Scientific) in PBS was dispensed into each droplet using I-DOT dispenser (Dispendix GmbH). 
DMA slide was incubated in cell culture incubator for 15 minutes and imaging was performed 
as described in section ‘Imaging of spheroids’.   
 
Drug treatment of HeLa cells in 3D spheroids and in 2D monolayer culture 
 For drug treatment HeLa cells were seeded onto DMA slides by dispensing cells in 
amount of 150 cells per 100 nL droplets and incubated either in upright or upside-down position 
for 2D and 3D cells culture, respectively. Spheroids from HeLa cells were grown for 48 hours 
before the drug treatment. For 2D cell culture experiments HeLa cells were incubated for 24 
hours before drug treatment. Afterwards, different concentration of three compounds, 
doxorubicin (European Pharmacopolia Reference Standards, European Directorate for the 
Quality of Medicines & Healthcare, Strasbourg, France), oxaliplatin (XX) and 5-Fluoruracil 
(XX) were dispensed with I-DOT dispenser (Dispendix GmbH) into droplets containing HeLa 
cells either in spheroids or in 2D monolayer. Compounds were diluted in DMEM medium 
containing 15% FCS and 1% penicillin/streptomycin till concentrations 0.15, 0.3, 1.5, 3, 4.5, 9, 
30 and 75 M and dispensed in amount of 50 nL into droplets of 100 nL resulting in final 
concentration in droplets 0.05, 0.1, 0.5, 1, 1.5, 3, 5, 10 and 25 M, respectively. After drug 
addition cells in both 2D and 3D cell culture were incubated for 48 hours. Afterwards, cells 
were stained with Calcein and PI and imaged as it is described in sections ‘Live/dead staining 
of spheroids’ and ‘Imaging of spheroids’, respectively.   
 
Image analysis  
 For monitoring spheroid growth over a period of 5 days (Fig. 3b) and estimation of 
dependence of spheroid size on initial cell number per spheroid (Fig. 3d), diameter of spheroids 
was measured manually in ImageJ software in brighfield images (Fig. 2d). For estimation of 
viability of spheroids cultured over a period of 10 days, ratio of Calcein positive area to 
combined Calcein and PI positive area was calculated (Fig. 3f). The Calcein and PI positive 
areas for live and dead part of a spheroid, respectively, were estimated using ImageJ software. 
To estimate the effect of the drugs, diameter of spheroids was measured in fluorescent images 
acquired in GFP channel showing Calcein (live) staining (Fig. 4). For estimation of viability of 
HeLa cells cultured in 2D monolayer, number of live and dead cells was counted in images 
acquired in GFP and mCherry channels, respectively, using ImageJ software (Fig. 4).     
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